MARC details
| 000 -LEADER |
|---|
| fixed length control field |
04020cam a2200565 i 4500 |
| 001 - CONTROL NUMBER |
|---|
| control field |
1411033330 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
OCoLC |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20250131161814.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS |
|---|
| fixed length control field |
m o d |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION |
|---|
| fixed length control field |
cr ||||||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
230517s2023 nju ob 001 0 eng |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9781119824572 |
| Qualifying information |
(ebook) |
|
|---|
| International Standard Book Number |
1119824575 |
|
|---|
| International Standard Book Number |
9781119824558 |
| Qualifying information |
(adobe pdf) |
|
|---|
| International Standard Book Number |
1119824559 |
|
|---|
| International Standard Book Number |
9781119824565 |
| Qualifying information |
(epub) |
|
|---|
| International Standard Book Number |
1119824567 |
|
|---|
| Canceled/invalid ISBN |
9781119824541 |
| Qualifying information |
(hardback) |
| 035 ## - SYSTEM CONTROL NUMBER |
|---|
| System control number |
(OCoLC)1411033330 |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
DLC |
| Language of cataloging |
eng |
| Description conventions |
rda |
| Transcribing agency |
DLC |
| Modifying agency |
OCLCO |
| -- |
DG1 |
| 042 ## - AUTHENTICATION CODE |
|---|
| Authentication code |
pcc |
| 050 00 - LIBRARY OF CONGRESS CALL NUMBER |
|---|
| Classification number |
RC280.L9 |
| 060 00 - NATIONAL LIBRARY OF MEDICINE CALL NUMBER |
|---|
| Classification number |
WH 525 |
| 245 00 - TITLE STATEMENT |
|---|
| Title |
Immunologic approaches for the treatment of lymphoid malignancies : |
| Remainder of title |
from concept to practice / |
| Statement of responsibility, etc. |
edited by Owen A. O'Connor, Stephen M. Ansell, John Gribben |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
|---|
| Place of production, publication, distribution, manufacture |
Hoboken, NJ : |
| Name of producer, publisher, distributor, manufacturer |
Wiley Blackwell |
| Date of production, publication, distribution, manufacture, or copyright notice |
2023 |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
1 online resource |
| 336 ## - CONTENT TYPE |
|---|
| Content type term |
text |
| Content type code |
txt |
| Source |
rdacontent |
| 337 ## - MEDIA TYPE |
|---|
| Media type term |
computer |
| Media type code |
c |
| Source |
rdamedia |
| 338 ## - CARRIER TYPE |
|---|
| Carrier type term |
online resource |
| Carrier type code |
cr |
| Source |
rdacarrier |
| 490 1# - SERIES STATEMENT |
|---|
| Series statement |
Precision cancer therapies ; |
| Volume/sequential designation |
volume 2 |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc. note |
|
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
"Optimizing an effective antitumor immune response has always been the goal of immunological strategies to treat cancer. It has been known for many years that the immune system plays a central role in cancer development and control; and promoting the immune response may be of profound therapeutic value. Patients with evidence of immunosuppression are at higher risk for cancer and while spontaneous remissions in certain cancers are uncommon, they are a well-recognized phenomenon. Additionally, there are reports of patients whose malignancy regressed at the time of an infectious episode suggesting that activation of the immune system promoted an anti-tumor effect. Furthermore, many indolent lymphomas follow a 'waxing and waning' course suggesting that the immune system may modulate progression of the disease. Understanding the components of an effective antitumor immune response, and developing strategies to optimize them, has led to remarkable advances in the treatment of cancer, particularly lymphoid malignancies. Some of the key steps in this process are highlighted below and the various components of immunotherapy in use to treat patients are discussed in the chapters that follow"-- |
| Assigning source |
Provided by publisher |
| 506 ## - RESTRICTIONS ON ACCESS NOTE |
|---|
| Terms governing access |
Available to OhioLINK libraries |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Cellular immunity. |
| Authority record control number or standard number |
https://id.loc.gov/authorities/subjects/sh85021695 |
|
|---|
| Topical term or geographic name entry element |
Lymphoma |
| General subdivision |
immunology. |
| Authority record control number or standard number |
https://id.nlm.nih.gov/mesh/D008223Q000276 |
|
|---|
| Topical term or geographic name entry element |
Lymphoma |
| General subdivision |
therapy. |
| Authority record control number or standard number |
https://id.nlm.nih.gov/mesh/D008223Q000628 |
|
|---|
| Topical term or geographic name entry element |
Immunotherapy |
| General subdivision |
methods. |
| Authority record control number or standard number |
https://id.nlm.nih.gov/mesh/D007167Q000379 |
|
|---|
| Topical term or geographic name entry element |
Immunoconjugates |
| General subdivision |
therapeutic use. |
| Authority record control number or standard number |
https://id.nlm.nih.gov/mesh/D018796Q000627 |
|
|---|
| Topical term or geographic name entry element |
Immunity, Cellular. |
| Authority record control number or standard number |
https://id.nlm.nih.gov/mesh/D007111 |
| 9 (RLIN) |
144365 |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
O'Connor, Owen A., |
| Authority record control number or standard number |
https://id.loc.gov/authorities/names/n2020184152 |
| Relator term |
editor |
| 9 (RLIN) |
143678 |
|
|---|
| Personal name |
Ansell, Stephen M., |
| Authority record control number or standard number |
https://id.loc.gov/authorities/names/no2008027310 |
| Relator term |
editor |
|
|---|
| Personal name |
Gribben, John, |
| Authority record control number or standard number |
https://id.loc.gov/authorities/names/n99044558 |
| Relator term |
editor |
| 710 2# - ADDED ENTRY--CORPORATE NAME |
|---|
| Corporate name or jurisdiction name as entry element |
Ohio Library and Information Network. |
| Authority record control number or standard number |
https://id.loc.gov/authorities/names/no95058981 |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY |
|---|
| Relationship information |
Print version: |
| Title |
Immunologic approaches for the treatment of lymphoid malignancies |
| Place, publisher, and date of publication |
Hoboken, NJ : Wiley Blackwell 2023 |
| International Standard Book Number |
9781119824541 |
| Record control number |
(DLC) 2023023583 |
| 830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE |
|---|
| Uniform title |
Precision cancer therapies ; |
| Authority record control number or standard number |
https://id.loc.gov/authorities/names/n2022184659 |
| Volume/sequential designation |
v. 2 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS |
|---|
| Materials specified |
OhioLINK |
| Public note |
Connect to resource |
| Uniform Resource Identifier |
<a href="https://rave.ohiolink.edu/ebooks/ebc2/9781119824572">https://rave.ohiolink.edu/ebooks/ebc2/9781119824572</a> |
|
|---|
| Materials specified |
Wiley Online Library |
| Public note |
Connect to resource |
| Uniform Resource Identifier |
<a href="https://onlinelibrary.wiley.com/doi/book/10.1002/9781119824572">https://onlinelibrary.wiley.com/doi/book/10.1002/9781119824572</a> |
|
|---|
| Materials specified |
Wiley Online Library |
| Public note |
Connect to resource (off-campus) |
| Uniform Resource Identifier |
<a href="https://go.ohiolink.edu/goto?url=https://onlinelibrary.wiley.com/doi/book/10.1002/9781119824572">https://go.ohiolink.edu/goto?url=https://onlinelibrary.wiley.com/doi/book/10.1002/9781119824572</a> |
